(P 0.001). Conclusions: We demonstrate that PCPs using a VTE call for considerably additional CVCs through treatment and that VTE sufferers have a greater % loss of CVCs in comparison to individuals devoid of a VTE. Future studies to decrease VTE and consequent CVC loss are prudent.PB1122|Janus Kinase 2 (JAK2V617F) Mutations in Sufferers with Splanchnic Vein Thrombosis, a Single Centre Encounter S. Chong; N.L. Mohd Ramli; E.S. Zulkefli; Z. Juhari; C.L. Phan; R. Hamzah; V. Selvaratnam; S.M. Tan Hospital Ampang, Ampang, Malaysia Background: The JAK2V617F mutation is recurrent in polycythaemia vera and important thrombocythaemia, that are myeloproliferative neoplasms often connected with arterial and venousPB1121|A Population-Based Descriptive Study of Long-term Anticoagulation within the Remedy and Leishmania Inhibitor list Secondary Prophylaxis of Venous Thromboembolism in Men with Prostate Cancer in Sweden Y. Balabanova1; B. Farahmand2; P. Stattin3; H. Garmo3; G. Brobertthromboembolism. It has also been reported as a marker for occult Myeloproliferative Neoplasm (MPN) in patients with splanchnic venous thrombosis. On the other hand, in comparison to JAK2V617F mutationpositive, individuals with an CALR mutation-positive present with significantly less danger of thrombosis. Aims: We evaluate the frequency of JAK2V617F and CALR mutations in individuals presenting with splanchnic vein thrombosis in samples sent to clinical Bcl-2 Inhibitor list referral Haematology Laboratory, Hospital Ampang, which can be the tertiary referral laboratory, the only laboratory supplied JAK2V617F and CALR mutational analysis for all hospitals inside the Ministry of Health in Malaysia. Methods: We retrospectively investigated each of the samples sent for JAK2V617F mutations from year 2016020 with presenting history of splanchnic vein thrombosis which involve: portal, splenic, hepatic and superior mesenteric vein thrombosis which are confirmed either by ultrasound or Computed tomography (CT) imaging. JAK2V617F mutation evaluation was done by Amplification Refractory Mutation Program (ARMS) PCR and CALR mutation analysis by High Resolution Melting (HRM). Benefits: Preliminary result of a total of 53 circumstances (29men and 24 females) with presenting history of splanchnic vein thrombosis was sent for screening of JAK2V617F in our database through 2016 and 2017. 13 individuals have been identified to possess the JAK2V617 mutation, plus the remaining of 40 sufferers were discovered to become adverse for each JAK2V617F and CALR mutation. Conclusions: Despite thrombosis becoming a frequent manifestation of Myeloproliferative Neoplasm(MPN), the role of screening the JAK2V617F mutations in all patients presenting with splanchnic vein thrombosis devoid of other capabilities of MPN is unclear. Nevertheless, the significance of screening for this mutation offers an accurate diagnosis and additional understanding the function of JAK2V617F mutation in thrombosis is often a wonderful prospective for the future development of therapeutics for illness intervention.Bayer AG, Berlin, Germany; 2Bayer AB, Stockholm, Sweden; 3UppsalaUniversity, Uppsala, Sweden Background: For many people with cancer-associated thrombosis, present recommendations propose anticoagulation, normally with lowmolecular weight heparin (LMWH) or possibly a non-vitamin K oral anticoagulant (NOAC); even so, the recommended duration varies. Observational information describing the anticoagulation received by men with prostate cancer in routine clinical practice are limited. Aims: We aimed to evaluate the variety and duration of long-term anticoagulant therapy prescribed for the therapy and second
